Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SK&F-105517 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| SK&F-105517 (COREG CR FDC) | DRUG | - |
Inclusion criteria: * Adult males or females of non-child bearing potential who are between 18 and 60 years old. * Have a history of mild to moderate essential hypertension or present with mild to moderate essential hypertension defined by Diastolic Blood Pressure \>/90 and \</109 mmHg, and/or Syst...
SK&F-105517 is an investigational small molecule being developed for the treatment of hypertension, a condition of high blood pressure. It is currently in Phase 1 clinical development, meaning it is still being tested in early-stage trials to evaluate its safety and how it works in the body.
SK&F-105517 is being developed by GSK plc, a global pharmaceutical company traded on the stock exchange under the ticker symbol GSK. The company is conducting clinical research on this drug candidate for hypertension.
SK&F-105517 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains in early-stage clinical testing for hypertension.
SK&F-105517 has one completed clinical trial registered under NCT00537043, titled "A Study to Compare COREG CR to COREG CR Fixed-dose Combination in Patients With High Blood Pressure." This Phase 1 study enrolled 24 participants with hypertension in the United States.
SK&F-105517 is not the same as COREG CR. The clinical trial NCT00537043 compares COREG CR to a fixed-dose combination that includes COREG CR, and SK&F-105517 is the investigational drug being studied in this context. They are distinct entities.